Literature DB >> 12409271

Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung lipofibroblasts.

László G Boros1, John S Torday, Wai-Nang Paul Lee, Virender K Rehan.   

Abstract

Preterm infants lack adequate surfactant production and often require oxygen support for adequate oxygenation. Prolonged oxygen treatment leads to the development of bronchopulmonary dysplasia (BPD), a disease process characterized by the blunting of alveolarization and proliferation of myofibroblasts. In the present study, we investigated metabolic adaptive changes in cultured fibroblasts isolated from immature (d18) and near-term (d21), fetal rat lungs in response to normoxic (21%) and hyperoxic (95%) exposures. We used the [1,2-13C2]D-glucose tracer and gas chromatography/mass spectrometry to characterize glucose carbon redistribution between the nucleic acid ribose, lactate, and palmitate synthetic pathways, and reverse transcriptase-polymerase chain reaction to assess adipose differentiation related protein (ADRP) mRNA expression in response to hyperoxic exposure. Exposure to hyperoxia at each passage caused decrease (*, p<0.05 vs. 21% O2) in ADRP mRNA expression in the d18 fibroblasts. This passage-dependent transdifferentiation is accompanied by a moderate (9-20%) increase in the synthesis of nucleic acid ribose from glucose through the non-oxidative steps of the pentose cycle. In contrast, d18 fibroblasts showed over an 85% decrease in the de novo synthesis of palmitate from glucose, while d21 fibroblasts showed a less pronounced 32-38% decrease in de novo lipid synthesis in hyperoxia-exposed cultures. It can be concluded from these studies that: (1) there is a maturation dependent sensitivity to hyperoxia; (2) transdifferentiation of flbroblast as demonstrated by changes in ADRP expression is accompanied by metabolic enzymes changes affecting ribose acid synthesis from glucose, and (3) hyperoxia specifically inhibits lipogenesis from glucose. Hyperoxia-induced metabolic changes thus play a key role in the transdifferentiation of lung fibroblasts to myofibroblasts and the pathogenesis of BPD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409271     DOI: 10.1016/s1096-7192(02)00140-3

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  21 in total

1.  Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury.

Authors:  Virender K Rehan; Reiko Sakurai; Julia Corral; Melissa Krebs; Basil Ibe; Kaori Ihida-Stansbury; John S Torday
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

Review 2.  Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.

Authors:  Laura Cerny; John S Torday; Virender K Rehan
Journal:  Lung       Date:  2008-01-30       Impact factor: 2.584

3.  Hyperoxia-induced NF-kappaB activation occurs via a maturationally sensitive atypical pathway.

Authors:  Clyde J Wright; Tiangang Zhuang; Ping La; Guang Yang; Phyllis A Dennery
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-12-12       Impact factor: 5.464

4.  Mechanism of reduced lung injury by high-frequency nasal ventilation in a preterm lamb model of neonatal chronic lung disease.

Authors:  Virender K Rehan; Jeanette Fong; Robert Lee; Reiko Sakurai; Zheng-Ming Wang; Mar Janna Dahl; Robert H Lane; Kurt H Albertine; John S Torday
Journal:  Pediatr Res       Date:  2011-11       Impact factor: 3.756

Review 5.  The lung alveolar lipofibroblast: an evolutionary strategy against neonatal hyperoxic lung injury.

Authors:  Virender K Rehan; John S Torday
Journal:  Antioxid Redox Signal       Date:  2014-03-12       Impact factor: 8.401

6.  Curcumin augments lung maturation, preventing neonatal lung injury by inhibiting TGF-β signaling.

Authors:  Reiko Sakurai; Yishi Li; John S Torday; Virender K Rehan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-05       Impact factor: 5.464

Review 7.  Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.

Authors:  Haifeng Zhao; Phyllis A Dennery; Hongwei Yao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-01-04       Impact factor: 5.464

8.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Authors:  Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

9.  Exploiting cellular-developmental evolution as the scientific basis for preventive medicine.

Authors:  J S Torday; V K Rehan
Journal:  Med Hypotheses       Date:  2009-01-14       Impact factor: 1.538

10.  Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease.

Authors:  K Takeda; M Okamoto; S de Langhe; E Dill; M Armstrong; N Reisdorf; D Irwin; M Koster; J Wilder; K R Stenmark; J West; D Klemm; E W Gelfand; E Nozik-Grayck; S M Majka
Journal:  Anat Rec (Hoboken)       Date:  2009-07       Impact factor: 2.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.